复方血栓通胶囊联合雷珠单抗治疗糖尿病视网膜病变的疗效及对血清hs-CRP、Ang-2水平的影响  

Efficacy of compound Xueshuantong capsule combined with ranibizumab in the treatment of diabetic retinopathy and its influence on serum hs-CRP and Ang-2 levels

作　　者：王军敬 吴秋云[1] 杨志强 Wang Jun-jing;Wu Qiu-yun;Yang Zhi-qiang(Department of Ophthalmology,The Second Affiliated Hospital of Luohe Medical College,Luohe 462300,Henan,China)

机构地区：[1]漯河医学高等专科学校第二附属医院眼科,河南漯河462300

出　　处：《四川生理科学杂志》2024年第1期100-102,205,共4页Sichuan Journal of Physiological Sciences

摘　　要：目的:探究复方血栓通胶囊联合雷珠单抗治疗糖尿病视网膜病变(Diabetic retinopathy,DR)的疗效及对促血管生成素(Angiopoietin-2,Ang-2)以及超敏C-反应蛋白(High-sensitivity C-reactive protein,hs-CRP)水平的影响。方法:选取2019年6月至2021年12月于我院确诊120例的双眼糖尿病视网膜病变患者作为研究对象,应用随机抽样法分为观察组和对照组,各60例(120眼)。对照组采用雷珠单抗注射治疗;观察组在对照组基础上增加口服复方血栓通胶囊。比较两组患者治疗前后的hs-CRP、Ang-2水平变化、黄斑中心凹厚度(Central macular thickness,CMT)、最佳矫正视力(Best-corrected visual acuity,BCVA)以及不良反应发生率。结果:治疗6 m后,两组患者hs-CRP水平、CMT明显下降,且观察组明显低于对照组(P<0.05);两组患者Ang-2水平、视力水平明显上升,且观察组明显高于对照组(P<0.05)。治疗后,观察组视力提高占比明显高于对照组,视力下降患者占比明显少于对照组(P<0.05)。两组不良反应总发生率无明显差异(P>0.05)。结论:复方血栓通胶囊联合雷珠单抗应用于糖尿病视网膜病变患者可有效降低hs-CRP、Ang-2水平,减轻视网膜水肿,提高患者视力,改善患者视功能,大大提高患者的生活质量。Objective:To explore the efficacy of compound Xueshuantong capsule combined with ranibizumab in the treatment of diabetic retinopathy(DR)and its influence on levels of serum angiopoietin-2(Ang-2)and serum high-sensitivity C-reactive protein(hs-CRP).Methods:A total of 120 patients(240 eyes)who were diagnosed with diabetic retinopathy in the hospital from June 2019 to December 2021 were selected as the research subjects,and were divided into two groups by the random sampling method,including observation group(n=60,120 eyes)and control group(n=60,120 eyes).The control group was treated with ranibizumab injection while the observation group was additionally given compound Xueshuantong capsule on the basis of the control group.The hs-CRP and Ang-2 levels,central macular thickness(CMT),best-corrected visual acuity(BCVA)and incidence rates of adverse reactions were compared between the two groups of patients before and after treatment.Results:After 6 months of treatment,the hs-CRP level was decreased while the Ang-2 level was increased in the two groups,and the hs-CRP in observation group was lower than that in control group while the Ang-2 was higher than that in control group(P<0.05).After 6 months of treatment,CMT in observation group was thinner than that in control group,and visual acuity was higher than that in control group(P<0.05).The proportion of visual acuity improvement in observation group after treatment was significantly more while the proportion of patients with decreased visual acuity was less compared with that in control group(P<0.05).After treatment,the total incidence rate of adverse reactions was 11.67% in observation group and that in control group was 8.33%(P>0.05).Conclusion:Compound Xueshuantong capsule combined with ranibizumab can effectively reduce the levels of hs-CRP and Ang-2,relieve the retinal edema,enhance the visual acuity,improve the visual function,and greatly promote the quality of life of patients with diabetic retinopathy.

关 键 词：复方血栓通胶囊 雷珠单抗 糖尿病视网膜病变 血清超敏C反应蛋白 促血管生成素 

分 类 号：R774.1[医药卫生—眼科] R587.1[医药卫生—临床医学]